✦ LIBER ✦

Predictors of Treatment with Osteoporosis Medications After Recent Fragility Fractures in a Multinational Cohort of Postmenopausal Women

✍ Scribed by Susan L. Greenspan; Allison Wyman; Frederick H. Hooven; Silvano Adami; Stephen Gehlbach; Frederick A Anderson Jr,; Steven Boone; Andrea Z. Lacroix; Robert Lindsay; J. Coen Netelenbos; Johannes Pfeilschifter; Stuart Silverman; Ethel S. Siris; Nelson B. Watts

Book ID: 114750329
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 116 KB
Volume: 60
Category: Article
ISSN: 0002-8614
DOI: 10.1111/j.1532-5415.2011.03854.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Strontium Ranelate Reduces the Risk of N

Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study

✍ Reginster, J. Y.; Seeman, E.; De Vernejoul, M. C.; Adami, S.; Compston, J.; Phen 📂 Article 📅 2005 🏛 Endocrine Society 🌐 English ⚖ 246 KB

A multifaceted intervention to improve t

A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial

✍ A. Cranney; M. Lam; L. Ruhland; R. Brison; M. Godwin; M. M. Harrison; M. B. Harr 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 147 KB

Effect of raloxifene after recombinant t

Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis

✍ S. Adami; J. San Martin; M. Muñoz-Torres; M. J. Econs; L. Xie; G. P. Dalsky; M. 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 187 KB

One year of treatment with PTH (1–84) an

One year of treatment with PTH (1–84) and the change in lumbar spine BMD in postmenopausal women with primary osteoporosis after pre-treatment with a bisphosphonate

✍ D. Hosking; M. Brandi; M. Díaz-Curiel; D. Felsenberg; L.H. Hyldstrup 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Comparison of bone architecture via micr

Comparison of bone architecture via micro-ct after long-term treatment with risedronate and alendronate: A cross-sectional study in women with postmenopausal osteoporosis

✍ T.E. Dufresne; P.A. Chmielewski; J.H. Nurre; B. Borah; X. Zhou; R.J. Phipps; G. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 63 KB

Bone material properties in actively bon

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

✍ Sonja Gamsjaeger; Birgit Buchinger; Elizabeth Zwettler; Robert Recker; Dennis Bl 📂 Article 📅 2010 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 473 KB

Zoledronic acid (ZOL), a third-generation aminobisphosphonate, showed pronounced antifracture efficacy in a phase III clinical trial [Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT)] when administered yearly (5-mg infusions of ZOL), produci